Afuco™ Anti-Human LTBR ADCC Therapeutic Antibody (BG9924), ADCC Enhanced
Anti-LTBR ADCC Enhanced Antibody (BG9924) is an ADCC enhanced antibody produced by our Afuco™ platform. The Phase II trial of baminercept (BG9924, LTβR-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. LTβR-Ig consists of the human LTβR extracellular domain fused to the human IgG1 Fc domain. It binds to LT α1/β2 and LIGHT ligands on activated lymphocytes and natural killer cells, blocking interactions with their receptors on peripheral antigen-presenting and stromal cells.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-484CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | LTBR |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Can be stored at 4°C. For long term storage, aliquot and store at -20°C. Avoid repeated freezing and thawing cycles. |